OUR PRODUCTS
FORMULATION

Each uncoated tablet contains Atenolol, 100mg

DOSAGE AND ADMINISTRATION

In the treatment of hypertension, Atenolol is given by mouth in a dose of 50 to 100 mg, 50 mg is generally adequate. The full effect is usually evident within 1 to 2 weeks. The usual dose for angina pectoris is 50 to 100 mg daily given as single or divided doses. For the emergency treatment of cardiac arrhythmia, Atenolol may be given through intravenous injection in a dose of 2.5 mg injected at a rate of 1 mg per minute, repeated if necessary every 5 minutes to maximum total dosage or 10 mg. Atenelol is also used as an adjunct in the elderly management of acute myocardial infarction to limit myocardial damage. Treatment should be given within 12 hours of the onset of chest pain.

INDICATION

For the management of hypertension, angina pectoris, cardiac arrhythmia and myocardial infarction.

PRECAUTIONS

Care should be taken with patients whose cardiac reserve is poor. Beta-adrenoreceptor blocking agents should be avoided in overt heart failure. However, they may be used in patients whose signs of failure have been completed. Atenolol may be used with caution in patients with chronic obstructive airways disease. However, some increase in airways resistance may occur occasionally in asthmatic patients. This can be reversed by the commonly used dosage of bronchodilators such as Salbutamol or Isoprenatine. Patients suffering from ischemic heart diseases, as with other beta-blocking agents, treatments should not be discontinued abruptly. In pregnancy and lactation, Atenolol has been used effectively under dose supervision for the treatment of pregnancy-associated hypertension. There was no evidence or fetal abnormalities. However, it is required that anticipated benefits be weighed against possible risks.

ADVERSE EFFECTS

Side effects are usually attributed to its pharmacological action and include coldness of the extremities, muscular fatigue and in isolated case, bradycardia. There has been a report of skin rashes and/or dry eyes associated with the use of beta-adrenergic blocking drugs.

GERMANY
KOHLENSERSLAUTERN
67663 KAISERSLAUTERN
GERMANY

ASIA PACIFIC - PHILIPPINES
2204-C West Tektite Tower, Philippine Stock Exchange Center Exchange Rd.,
Ortigas Center, Pasig City,
Philippines

EMAIL
eisaac@verheilenpharma.com
info@verheilen.com
info@verheilenpharma.com

Powered by Strategist.ph | Verheilen Pharmaceuticals Inc. © 2015 All rights reserved.

Translate »